FRI0204 Long-term benefits of 4-weekly certolizumab pegol monotherapy and combination therapy on household productivity and social participation in rheumatoid arthritis: 5-year results from an open-label extension study

2013 ◽  
Vol 72 (Suppl 3) ◽  
pp. A441.2-A442 ◽  
Author(s):  
V. Strand ◽  
O. Purcaru ◽  
R. van Vollenhoven ◽  
E. Choy ◽  
R. Fleischmann
Keyword(s):  
Rheumatoid Arthritis ◽  
Combination Therapy ◽  
Social Participation ◽  
Certolizumab Pegol ◽  
Extension Study ◽  
Open Label ◽  
Open Label Extension ◽  
Household Productivity

SAT0151 Long-term safety of 4-weekly certolizumab pegol in rheumatoid arthritis: 5 year results from an open label extension study:

2013 ◽  
Vol 71 (Suppl 3) ◽  
pp. 523.1-523 ◽  
Author(s):  
R. Fleischmann ◽  
R. van Vollenhoven ◽  
J. Vencovsky ◽  
R. Alten ◽  
O. Davies ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Certolizumab Pegol ◽  
Extension Study ◽  
Open Label ◽  
Open Label Extension

scholarly journals An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis

2019 ◽  
Vol 21 (1) ◽  
Author(s):  
Stanley Cohen ◽  
Jose L. Pablos ◽  
Karel Pavelka ◽  
Gerard Anton Müller ◽  
Alan Matsumoto ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Extension Study ◽  
Open Label ◽  
Safety And Efficacy ◽  
Open Label Extension ◽  
Abp 501
Sign in / Sign up

Export Citation Format

Share Document